Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lexapro Prescribers: Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 7, 2008
Exciting new treatment for OCD and Social Anxiety Disorder
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
1. Controlled release preparations are often better tolerated with fewer side effects than immediate release preparations 2. OCD and SAD are severe, highly prevalent and chronically disabling conditions 3. Despite presence of SSRIs and other treatment, e.g, cognitive behavioral therapy, up to 1/3 of...
March 7, 2008
FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance
Analysis of: U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) | pharmalive.com
Author: GLG Expert Contributor
1. Despite common use of multiple psychotropic medications for bipolar disorder in youth, there are few FDA-approved treatments 2. Abilify is one of the safest and best tolerated of the atypical antipsychotics with fewer side effects than some of the other atypical antipsychotic medications 3. This...
February 27, 2008
Eli Lilly & Company Develops Novel Antipsychotic for Treating Schizophrenia
Analysis of: Daring to Think Differently About Schizophrenia | www.nytimes.com
Author: GLG Expert Contributor
All currently marketed antipsychotic medications for treating  schizophrenia  rely on mechanisms of action  which target  dopamine and  serotonin receptors.  Although these medications reduce delusions and hallucinations without inducing symptoms of Parkinson's Disease...
February 7, 2008
Lilly's (LLY) Long-Acting Zyprexa May Have a Role in Non-Compliant Patients
Analysis of: Lilly Gets Support for Version | online.wsj.com
Author: GLG Expert Contributor
Lilly's new Long-Acting Zyprexa will face FDA panel scrutiny and a likely focus of concern will be the sedation problem occurring in some patients soon after injection.  However, this should not be a deal-breaker..given the high degree of efficacy of this medication in schizoprenic (and bipolar...
February 7, 2008
Somaxon's (SOMX) Silenor: Recycling Old Drugs
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia | www.pipelinereview.com
Author: GLG Expert Contributor
Doxepin HCL has a long history of use both as an antidepressant and for its hypnotic effect.  What does this reincarnation of an old (but good) drug add to the marketplace...and why would it be successful?
February 5, 2008
More questions raised than answers
Analysis of: Chantix And Suicide: The Latest Numbers | www.pharmalot.com
Author: GLG Expert Contributor
No good data that Chantix is associated with suicide Need more controlled research to answer questions Scary adverse events are not the same as side effects directly linked to medication
January 9, 2008
Not Another mGluR Drug: The Competition Is On.
Analysis of: Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate | www.pipelinereview.com:80
Author: GLG Expert Contributor
Pfizer Inc (NYSE:PFE) and Taisho Pharmaceutical Co., Ltd. (OTC:TSOPF.PK) announced the signing of a definitive agreement for worldwide collaboration to research, develop and commercialize TS-032.   TS-032 is a metabotropic glutamate receptor (mGluR) agonist, a novel drug candidate for the...
January 8, 2008
Merck’s Agreement With Addex To Develop ADX63365: Eli Lilly May Have Competition In Groundbreaking Glutamate-Based Treatment of Schizophrenia.
Analysis of: Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia | www.pipelinereview.com:80
Author: GLG Expert Contributor
Addex Pharmaceuticals (Swiss:ADXN.SW) announced on January 3, 2008 an exclusive worldwide license agreement with Merck & Co., Inc. (NYSE:MRK) to develop ADX63365, a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5) with potential for the...
December 26, 2007
Cymbalta (Eli Lilly: LLY) Gets FDA Seal of Approval for Long-term Depression Management
Analysis of: FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder | www.prnewswire.com
Author: GLG Expert Contributor
Cymbalta (Eli Lilly: LLY) solidifies its place in the depression marketplace with this new FDA approval for maintenance treatment.  The incrementaL impact on sales is another matter.
December 21, 2007
EPIX Pharmaceuticals’ PRX-03140 Demonstrates Short-Term Pro-cognitive Effects In Patients With Alzheimer’s Disease, Longer Studies Are Needed To Evaluate It’s Potential Disease Modifying Effects.
Analysis of: EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease | www.pipelinereview.com
Author: GLG Expert Contributor
1. The results of this study demonstrtae a treatment in development, PRX-03140, which may provide stronger pro-cognitive effects than those currently available for Alzheimer's disease. 2. PRX-03140 may be a disease altering alternative to other treatments currently in development. 3. The mechanism...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 157

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613